









Markets
/
Stocks
/
nasdaq-ibo
/

Impact Biomedical Inc

IBO

0.545USD

+0.012+2.27%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

6.64MMarket Cap

LossP/E TTM



Impact Biomedical Inc

0.545

+0.012+2.27%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Impact Biomedical Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Impact Biomedical Inc's Score

Industry at a Glance

Industry Ranking

305 / 501

Overall Ranking

591 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Impact Biomedical Inc Highlights

StrengthsRisks

Impact Biomedical Inc. is a human healthcare company and is a wholly owned subsidiary of DSS, Inc. The Company, through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the bio health and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The Company, through its subsidiary, Global BioLife, Inc., focuses on research in four main areas: the Linebacker project, which develops a universal therapeutic drug platform; a new sugar substitute called Laetose; a multi-use fragrance called 3F (Functional Fragrance Formulation), which is a mosquito fragrance product; and Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.17, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 508.04K shares, increasing 15.77% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Impact Biomedical Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 8.20, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.17, which is -8.28% below the recent high of -0.16 and -1168.00% above the recent low of -2.16.

Score

Industry at a Glance

Previous score

8.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 305/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.04.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 4.13, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 0.64 and the support level at 0.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.51

Change

-0.38

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.011

Sell

RSI(14)

27.723

Sell

STOCH(KDJ)(9,3,3)

23.164

Neutral

ATR(14)

0.025

High Vlolatility

CCI(14)

-134.914

Sell

Williams %R

77.237

Sell

TRIX(12,20)

-0.594

Sell

StochRSI(14)

45.878

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

0.539

Buy

MA10

0.561

Sell

MA20

0.583

Sell

MA50

0.617

Sell

MA100

0.631

Sell

MA200

0.875

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Chan (Heng Fai Ambrose)

351.56K

-91.76%

BlackRock Institutional Trust Company, N.A.

252.73K

+723.90%

Heuszel (Frank D.)

95.47K

Geode Capital Management, L.L.C.

49.87K

+114.95%

UBS Financial Services, Inc.

39.73K

+145.72%

The Vanguard Group, Inc.

Star Investors

32.44K

-74.35%

Susquehanna International Group, LLP

30.82K

Two Sigma Investments, LP

22.70K

Document Security Systems, Inc.

21.26K

-88.33%

State Street Investment Management (US)

11.80K

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.